Evaluation of ESBL positivity rates for Escherichia coli and Klebsiella pneumoniae strains with the sensititre ESBL antibiotic susceptibility plates in a public hospital, Turkey

Journal of Medical Sciences

Volumn 9, Issue 2, 2009, Pages 103-107

  Arabaci, Filiz ^a   Oldacay, M ^a   Berber, D ^a  

^a Canakkale State Hospital   (Turkey)

Author keywords

E. coli K. pneumonia; ESBL; ICU; Inpatient clinics

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOXITIN; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; ENZYME SYNTHESIS; ESCHERICHIA COLI; HOSPITALIZATION; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; NONHUMAN; PUBLIC HOSPITAL; RISK FACTOR; TURKEY (REPUBLIC);

EID: 67649886120     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2009.103.107     Document Type: Article

References (23)

1. Bradford, P.A., 2001. Extended-spectrum beta-lactamases in the 21st century: Charasterization, epidemiology and detection of this important resistance threat. Clin. Microbiol. Rev., 14: 933-951.
2. Buluc, M., M. Gurol and C. Bal, 2003. Rates of extended spectrum beta lactamases: 2000-2002. Turk. Mikrobiyol. Cem. Derg., 33: 31-34 (In Turkish).
3. Bush, K., G.A. Jacoby and A.A. Medeiros, 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother., 39: 1211-1233.
4. Bush, K., 2002. The impact of beta-lactamases on the development of novel antimicrobial agents. Curr. Opin. Investig. Drugs, 3: 1284-1290.
5. Chanawong, A., F.M., M'Zali, J. Heritage, J.H. Xiong and P.M. Hawkey, 2002. Three cefotaximases, CTX-M-9, CTX-M-13 and CTX-M-14, among enterobactericeae in the Peoples Rebublic of China. Antimicrob Agents Chemother., 46: 630-637.
6. Chapin, K.C. and M.C. Musgnug, 2004. Evaluation of sensititre automated reading and Incubation system for automated reading of sensititre broth microdilution susceptibility plates. J. Clin. Microbiol., 42: 909-911.
7. CLSI., 2006. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A7. 7th Edn., Clinical and Laboratory Standards Institute, Wayne, PA.
8. CLSI., 2007. M100-S17, Performance Standards for Antimicrobial Susceptibility Testing. 17th Informational Supplement Clinical and Laboratory Standards Institute, Wayne, PA.
9. Gunseren, F., L. Mamikoglu, S. Ozturk, M. Yucesoy, K. Biberoglu and N. Yulug et al., 1999. A surveillance study of antimicrobial resistance of Gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J. Antimic. Chemother., 43: 373-378.
10. Jones, R.N., 2001. Global aspects of antimicrobial resistance among key bacterial pathogens. Results from the 1997-1999 SENTRY antimicrobial program. Clin. Infect. Dis., 32: 81-156.
11. Jones, R.N., M.A. Pfaller and The MYSTIC Study Group (Europe), 2003. Antimicrobial activity against strains of Escherichia coli and Klebsiella sp. with resistance phenotypes consistent with an extended spectrum beta- lactamase in Europe. Clin. Microb. Infect. Dis., 9: 708-712.
12. Livermore, D.M. and M. Yuan, 1996. Antibiotic resistance and production of extended spectrum beta-lactamases amongst Klebsiella sp. from intensive care unit Europe. J. Antimicrob. Chemother., 38: 409-424.
13. Medeiros, A.A., 1997. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin. Infect. Dis., 24: S19-S45.
14. Moland, E.S., N.D. Hanson, J.A. Black, A. Hossain, W. Song and K.S. Thomson, 2006. Prevalence of newer β-lactamases in Gram-negative clinical isolates collected in the United States from 2001 to 2002. J. Clin. Microbiol., 44: 3318-3324.
15. Mugnier, P., I. Casin, A.T. Bouthors and E. Collatz, 1998. Novel OXA-10-derived extended-spectrum beta-lactamases, selected in vivo or in vitro. Antimicrob. Agents Chemother., 42: 3113-3116.
16. Ozakin, C., M. Smirtas, E. Sevgican, E. Kazak and S. Gedikoglu, 2003. Comparison of the E-test method with an automated bacterial identification and antimicrobial susceptibility detection system for screening extended-spectrum beta-lactamase producers. Scand. J. Infect. Dis., 35: 700-703.
17. Paterson, D.L., L. Mulazimoglu and M.L. Casellas, 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect. Dis., 30: 473-478.
18. Paterson, D.L., W.C. Ko, A. von Gottberg, S. Mohapatra, M. Casellas, and H. Goossens et al., 2004. International prospective study of Klebsiella pneumoniae bacteriemia: Implications of extended spectrum beta-lactamase production in nosocomial infections. Ann. Int. Med., 140: 26-32.
19. Paterson, D.L. and R.A. Bonomo, 2005. Extended-spectrum beta-lactamases: A Clinical Update. Clin. Microbiol. Rev., 18: 657-686.
20. Poutsiaka, D.D., 2001. Antimicrobial resistance in the chronically critically ill patient. Clin Chest Med., 22: 87-103.
21. Rodriquez, B.J., M.D. Navarro, L. Romero, M.A. Muniain and M. de Cueto et al., 2006. Bacteriemia due to extended due to extended spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: A new clinical chalange. Clin. Infect. Dis., 43: 1407-1414.
22. Woodford, N., M.E. Ward, M.E. Kaufmann, J. Turton and E.J. Faqan et al., 2004. Community and hospital spread of Escherichia coli producing CTX-M extended spectrum beta-lactamases in the UK. J. Antimicrob. Chemother., 54: 735-743.
23. Zarakoglu, P., G. Metan, O. Hascelik and M. Akova, 2007. Prevalance of extended spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella sp. strains isolated from blood cultures. Microbiyol. Bult., 41: 579-584 (In Turkish).